Skip to main content

Table 4 Comparison of neurological symptoms between patients with and without HP

From: Hypertrophic pachymeningitis in ANCA-associated vasculitis: a cross-sectional and multi-institutional study in Japan (J-CANVAS)

 

Total AAV

Newly diagnosed AAV

Relapsed AAV

HP (n = 30)

Non-HP (n = 633)

p-values

HP (n = 20)

Non-HP (n = 538)

p-values

HP (n = 10)

Non-HP (n = 95)

p-values

Nervous system, number (%)

 Headache

21 (70)

34 (5.7)

< 0.0001

16 (80)

29 (5.4)

< 0.0001

5 (50)

10 (11)

0.005

 Meningitis

3 (10)

2 (0.3)

0.0007

1 (5)

1 (0.2)

0.071

2 (20)

1 (1.1)

0.023

 Organic confusion

1 (3.3)

6 (0.9)

0.278

1 (5)

6 (1.1)

0.227

0

0

–

 Seizures

0

4 (0.6)

1

0

2 (0.3)

1

0

2 (2.1)

0.999

 Stroke

0

9 (1.4)

0.999

0

8 (1.5)

0.999

0

1 (1.1)

0.999

 Spinal cord lesion

3 (10)

2 (0.3)

0.0008

1 (5)

1 (0.2)

0.007

2 (20)

1 (1.1)

0.023

 Cranial nerve palsy

10 (33)

19 (3)

< 0.0001

5 (25)

15 (2.8)

0.0003

5 (50)

4 (4.2)

0.003

 Sensory peripheral neuropathy

3 (10)

166 (26)

0.052

3 (15)

145 (27)

0.307

0

21 (22)

0.206

 Mononeuritis multiplex

0

105 (17)

0.009

0

93 (17)

0.034

0

12 (13)

0.599

  1. Statistical significance was set at a p-value < 0.05
  2. ANCA antineutrophil cytoplasmic antibody, AAV ANCA-associated vasculitis, HP hypertrophic pachymeningitis